Evaxion Biotech A/S
EVAX
$1.65
$0.063.77%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | 55.97% | 49.12% | 49.12% |
| Total Depreciation and Amortization | -- | -- | -44.83% | 124.13% | 124.13% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | 693.98% | 183.46% | 183.46% |
| Change in Net Operating Assets | -- | -- | 159.54% | 18.25% | 18.25% |
| Cash from Operations | -- | -- | 75.18% | 57.52% | 57.52% |
| Capital Expenditure | -- | -- | 78.08% | 99.24% | 99.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -100.00% | -117.86% | -117.86% |
| Cash from Investing | -- | -- | 76.12% | 98.20% | 98.20% |
| Total Debt Issued | -- | -- | -99.17% | -100.24% | -100.24% |
| Total Debt Repaid | -- | -- | 44.10% | 51.62% | 51.62% |
| Issuance of Common Stock | -- | -- | 646.50% | -97.95% | -97.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 123.23% | 123.23% |
| Cash from Financing | -- | -- | -31.82% | -97.99% | -97.99% |
| Foreign Exchange rate Adjustments | -- | -- | 46.03% | 127.21% | 127.21% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | 91.91% | -255.39% | -255.39% |